Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003 in Stable COPD Patients
NCT04087590Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Jan 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BEVESPI AEROSPHERE in chronic obstructive pulmonary disease (COPD), sponsored by CHU de Lille. Primary endpoint: Tidal volume (VT) complexity (noise limit) at 1 month. Started Jan 2020; status: terminated.
02
Drugs
BEVESPI AEROSPHERE
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04087590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087590.